Vaxcyte Stock Spikes 27% as Lead Vaccine Candidate Takes Aim at Pfizer and Merck
Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says.
Vaxcyte is poised to capture significant share of a $3 billion to $6 billion market following the latest trial results, Jefferies says.